开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
德意志银行股价创下自2011年7月以来的最高点,涨4.5%。
2026-08-26
德意志银行股价创下自2011年7月以来的最高点,涨4.5%。
返回
其他消息
2026-08-27
Padhraic Garvey, head of Americas research, and Michiel Tukker, senior rates strategist at ING, say the US 10-year Treasury yield is unlikely to fall below 4.5% in the near term. They add the US Treasury’s repo plan won the first round in lowering long-term yields but warned more battles lie ahead; if the repo programme aims to structurally push long-term yields lower, a tougher fight remains. ING expects the 10-year to trade in a 4.5%-5% range, with upside pressure toward 4.75%-5% still present
Padhraic Garvey, head of Americas research, and Michiel Tukker, senior rates strategist at ING, say the US 10-year Treasury yield is unlikely to fall below 4.5% in the near term. They add the US Treasury’s repo plan won the first round in lowering long-term yields but warned more battles lie ahead; if the repo programme aims to structurally push long-term yields lower, a tougher fight remains. ING expects the 10-year to trade in a 4.5%-5% range, with upside pressure toward 4.75%-5% still present.
2026-08-26
The FDA has approved Revolution Medicines' pancreatic cancer drug Daraxonrasib, which will be marketed as Rasonque. The drug is the first therapy targeting one of the disease's key molecular pathogenic mechanisms. A late-stage trial published in May showed Daraxonrasib nearly doubled typical survival in an aggressive form of pancreatic cancer to 13.2 months versus 6.7 months with chemotherapy, the current standard of care.
The FDA has approved Revolution Medicines' pancreatic cancer drug Daraxonrasib, which will be marketed as Rasonque. The drug is the first therapy targeting one of the disease's key molecular pathogenic mechanisms. A late-stage trial published in May showed Daraxonrasib nearly doubled typical survival in an aggressive form of pancreatic cancer to 13.2 months versus 6.7 months with chemotherapy, the current standard of care.
Chat with us
, powered by
LiveChat